하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
HIRONIC, a global medical aesthetic device company marking its 20th anniversary in 2026, announced today that its MIGLOU™ device has received medical device approval from Korea's Ministry of Food and Drug Safety (MFDS). The approval adds MIGLOU™ to HIRONIC's growing portfolio of MFDS-certified technologies, reinforcing the company's continued investment in clinically validated, next-generation aesthetic solutions for medical professionals worldwide.
A New Approach to Skin Tightening and Contouring
MIGLOU™ is built on HIRONIC's proprietary 2.45GHz Focused Intensive Microwave (FIM) technology, engineered to deliver targeted energy for skin tightening and contouring treatments. The platform reflects HIRONIC's ongoing commitment to developing differentiated technologies that address evolving needs in the medical aesthetics field. The approval marks another step in HIRONIC's 20th anniversary year, reflecting the company's continued focus on research-driven development and a regulation-first approach to bringing new technologies to the global aesthetic market.
Strengthening HIRONIC's Global Technology Portfolio
The MFDS approval positions MIGLOU™ alongside HIRONIC's established device lines — including New Doublo™, SYNERJET PRO™, and PICOHI™ — as part of a comprehensive technology platform serving medical aesthetic partners in more than 60 countries. With MFDS, FDA, and CE certifications across its portfolio, HIRONIC continues to expand its footprint through a rigorous, regulation-first approach to product development.
About HIRONIC
Founded in 2006, HIRONIC is a KOSDAQ-listed medical aesthetic device company celebrating its 20th anniversary in 2026. HIRONIC develops and manufactures energy-based aesthetic devices distributed across more than 60 countries, with a portfolio spanning HIFU, RF, laser, and needle-free delivery technologies.
